Welcome to our dedicated page for Cardiac Biotech Solutions news (Ticker: CBSC), a resource for investors and traders seeking the latest updates and insights on Cardiac Biotech Solutions stock.
Cardiac Biotech Solutions, Inc. (CBSC) develops, manufactures, and distributes non-invasive ambulatory cardiac monitoring products for remote electrocardiogram data collection. Company news centers on the MyCardia AT cardiac event monitor, also branded as CardioHolter AT in Canada, and related cloud-based acquisition software and mobile applications for iOS, Android, and WeChat.
Recurring updates include regulatory clearances and market-entry work for cardiac monitoring devices, manufacturing and production arrangements, hospital and distributor deployments, international distribution agreements, device purchase orders, and rental programs that pair monitoring hardware with cloud platform access. News also covers corporate-status and governance items such as the company name change, OTC market status, and executive appointments.
CB Scientific (OTC PINK:CBSC) has announced a partnership with Shenzhen Pump Medical System Co., Ltd. to manufacture medical products aimed at the Southeast Asian market. This collaboration is crucial for establishing local manufacturing capabilities and securing necessary FDA and NMPA approvals. CEO Charles Martin emphasized the importance of this relationship for regulatory validation and gaining access to regional distribution channels. The company plans to provide updates on future developments to shareholders and the public.
CB Scientific Inc. (OTC PINK:CBSC) announced a Special Stockholder Meeting to approve enhancements aimed at positioning the company for growth. The meeting will address a corporate name change, relocation for tax advantages, increased authorized shares for fundraising, and a ratification of the 2021 Omnibus Stock Incentive Plan. Management believes recent progress in Southeast Asia and an application to up list to the OTCQB creates the momentum needed for these changes. Details on the meeting date will be provided in the coming weeks.
CB Scientific (OTC PINK:CBSC) announced its application for uplisting to the OTCQB Venture Market. This move is aimed at enhancing trading efficiency and transparency. While the submission does not guarantee acceptance, the company has completed necessary steps, including a PCAOB audit and appointing independent directors. CEO Charles Martin emphasized that uplisting would position CBSC better for future goals, including a potential shift to Nasdaq. The company anticipates that uplisting will lead to improved compliance, reporting standards, and analyst coverage.
CB Scientific Inc. (OTC PINK:CBSC) has appointed Brooke Martellaro as its new Chief Financial Officer, effective immediately. Martellaro brings extensive experience from various corporations, enhancing the company's executive management. Her immediate focus includes collaborating with MaloneBailey LLP to conclude a PCAOB audit, vital for CBSC’s transition to the OTCQB Venture Market. The company emphasizes that Martellaro's financial expertise will significantly contribute to strategic and operational improvements, facilitating long-term success.
CB Scientific has appointed Paul K. Danner as Chairman of its Board of Directors, effective immediately. Danner brings over 25 years of experience with Nasdaq-listed companies. His leadership aims to enhance the company’s executive team amid plans for a timely uplist to the OTCQB Venture Market, pending a completed audit by MaloneBailey LLP. Danner expressed excitement about the company’s growth potential, focusing on expanding both domestically and internationally. CB Scientific provides innovative cardiac monitoring solutions, emphasizing their commitment to transparency with future announcements.
CB Scientific Inc. (OTC PINK: CBSC) has initiated an independent financial audit with MaloneBailey, LLP to assess its financial statements as of March 31, 2021. This audit is crucial for the company's objective to uplist from OTC Pink to OTCQB, requiring PCAOB compliance. The audit will provide insights into CBSC's internal controls and offer a comprehensive overview of its financial health. The process is expected to conclude within eight weeks, ensuring transparency as the company aims to keep its investors informed of any developments.
CB Scientific Inc. (OTC PINK:CBSC) has launched the Heart Wellness Check-Up program in Bangkok, Thailand, through Mango Wellness and My Cardia Thailand. This new direct-to-consumer service enables remote cardiac monitoring via 26 pharmacies and clinics. The program allows customers to monitor heart health at home for 10 days using CBSC's my-Cam™ monitor, with data transmitted to a cloud-based portal. Several major hospitals are involved, and the initiative aims to address cardiac care during the COVID-19 pandemic.
CB Scientific (OTC PINK:CBSC) announced a consultancy agreement with the Dorchester Group, led by Robert H. Hesse, to enhance its financing and marketing strategies in the U.S. and Southeast Asia. The company is expanding its Remote Cardiac Monitoring services through a distributor, Mango Wellness, collaborating with three major Thai hospitals. This initiative aims to roll out CB Scientific's my-Cam remote monitoring products. The CEO emphasized that the partnership would assist in navigating regulatory approvals, especially for its my-Cam device in mainland China.
CB Scientific, Inc. (CBSC) announced a significant partnership with three major hospital chains in Thailand to implement Remote Cardiac Monitoring Services using their my-Cam device. This agreement follows successful trials with a diagnostic success rate of 85%. The hospitals involved are Ramkhamhaeng Hospital, Bangkok Hospital Nakon Ratchasima, and Bangpakok9 Hospital. The initiative, managed through Mango Wellness Co., Ltd., aims to enhance cardiac event monitoring and improve patient outcomes. Future expansions into government hospitals are also underway.
CB Scientific (OTC PINK:CBSC) announces its acquisition of Cardiolink Corporation, a Medicare-certified Independent Diagnostic Testing Facility (IDTF) in New York, to enhance its position in the US Remote Patient Monitoring market. This strategic move aims to meet the rising demand for cardiac monitoring services, projected to grow at 18% annually from a 2019 revenue of $778M. The acquisition is expected to conclude by May 2021, aligning with CBSC's goal to address the health impacts of cardiovascular disease, which claims over 655,000 American lives yearly.